First, of course, laws differ by country, so researchers are advised to check local laws and regulations before placing an order
The researchers recommend the use of subcutaneous semaglutide as a part of a comprehensive weight loss management program for individuals who are overweight or obese
No logos from publications plastered across the site without proof
TLDR: "Discontinuation of GLP-1RA treatment leads to weight regain, regardless of lifestyle interventions, and should therefore be considered a chronic therapy to prevent weight regain and associated undesirable outcomes related to obesity." Key findings: After stopping liraglutide, patients regained ~2.2 kg After stopping semaglutide/tirzepatide, patients regained ~9.7 kg Weight regain was proportional to initial weight loss Lifestyle changes alone DID NOT prevent regain Implication: GLP-1 receptor agonists are not a short-term solution
Portugal-Cohen M, Oron M, Merrik E, Ben-Amitai D, Yogev H, Zvulunov A (2011) A dead sea water-enriched body cream improves skin severity scores in children with atopic dermatitis
*Investigational Dose of Semaglutide Shows 20.7% Weight Loss at 72 Weeks.* January 2025